Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Dr. Solange Peters at ITCD2026 outlines rationale for targeting immune checkpoints with bispecific antibodies. Is it two drugs for one? Will this trigger more immune mediated responses and long term survival?”
More posts featuring Stephen Liu on OncoDaily.
